At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with ...

Terns Pharmaceuticals, Inc. ( TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia December 8, 2025 4:30 PM EST ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients ...

This was not the first presentation on STI-571, but it was the one that would change everything: The New England Journal of ...

In chronic myeloid leukemia, combining asciminib with a tyrosine kinase inhibitor shows increasing efficacy and tolerability over 3 years.

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

Orca Bio presents positive new data from its pipeline of allogeneic T-cell immunotherapies at the 67th ASH Annual Meeting.

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...